Robert E. Gagnon, Chief Financial Officer at Opus Genetics, Inc. (IRD), sold 28,000 shares at $4.54 ($127K) on 2026-09-03, disclosed to the SEC on 2026-09-08.
Scheduled sale ($127k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VSTM | SELL | 2025-12-18 | $3K | — | Filing → |
| VSTM | SELL | 2025-09-18 | $3K | — | Filing → |
| VSTM | SELL | 2025-06-20 | $2K | — | Filing → |